Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Stephane Thibodeau"'
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 45, Iss , Pp 100728- (2024)
Externí odkaz:
https://doaj.org/article/82e131db0e1f4b62b87ce43fb1432d92
Autor:
Maria Thereza Mansur Starling, Stephane Thibodeau, Cecília Félix Penido Mendes de Sousa, Felipe Cicci Farinha Restini, Gustavo A. Viani, Andre G. Gouveia, Lucas C. Mendez, Gustavo Nader Marta, Fabio Ynoe Moraes
Publikováno v:
Cancers, Vol 16, Iss 3, p 539 (2024)
The global cancer burden, especially in low- and middle-income countries (LMICs), worsens existing disparities, amplified by the rising costs of advanced treatments. The shortage of radiation therapy (RT) services is a significant issue in LMICs. Ext
Externí odkaz:
https://doaj.org/article/20feffad06fd464490972ae55bad22e0
Autor:
Stephane Thibodeau, Mahbuba Meem, Wilma Hopman, Simran Sandhu, Osbert Zalay, Andrea S. Fung, Adi Kartolo, Geneviève C. Digby, Shahad Al-Ghamdi, Andrew Robinson, Allison Ashworth, Timothy Owen, Aamer Mahmud, Kit Tam, Timothy Olding, Fabio Ynoe de Moraes
Publikováno v:
Cancer Treatment and Research Communications, Vol 36, Iss , Pp 100747- (2023)
Purpose/Objective: Around 30% of patients with non-small cell lung cancers (NSCLC) are diagnosed with stage III disease at presentation, of which about 50% are treated with definitive chemoradiation (CRT). Around 65–80% of patients will eventually
Externí odkaz:
https://doaj.org/article/3d8d681f93cc4264a88179a2b79a4362
Publikováno v:
European Journal of Breast Health, Vol 15, Iss 3, Pp 163-170 (2019)
Objective: To determine the influence of the Oncotype Dx assay on the treatment of patients with Estrogen Receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative, axillary lymph node-negative or micrometastatic carcinoma of t
Externí odkaz:
https://doaj.org/article/44346e248a2b4dd89e6b2cb4d9e80769
Publikováno v:
Journal of Clinical Medicine, Vol 7, Iss 1, p 7 (2018)
The introduction of the FOLFIRINOX regimen within the last decade marked the first progress in the clinical field of metastatic pancreatic cancer which had not seen any improvements in treatment availability for several years. In a phase III randomiz
Externí odkaz:
https://doaj.org/article/66ea16fcb0a84d758d2d1b257e8bc3be
Publikováno v:
Radiotherapy and Oncology. 174:S61
Publikováno v:
Hematology/Oncology and Stem Cell Therapy, Vol 12, Iss 2, Pp 89-96 (2019)
Objective/Background: The Oncotype Dx test is a genomic test currently used in clinical practice to predict the risk of disease recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer patients with axillary lymph node-negative or m
Autor:
Richard Sullivan, Christopher M. Booth, Stephane Thibodeau, Timothy P. Hanna, Ajay Aggarwal, Will D. King, Gregory A. Paulin, Dylan E O'Sullivan, Elizabeth Harvey-Jones, Matthew Jalink
Publikováno v:
The BMJ
BMJ
BMJ
Objective To quantify the association of cancer treatment delay and mortality for each four week increase in delay to inform cancer treatment pathways. Design Systematic review and meta-analysis. Data sources Published studies in Medline from 1 Janua
Publikováno v:
Nephrology. 25:29-31
Introduction: Kidney is one of the major target organs of COVID-19 Importantly, COVID-19 patients with kidney manifestations had significantly increased rate of hospital mortality Most COVID-19 kidney cohorts were done solely in hospitalized patients
Publikováno v:
European journal of breast health. 15(3)
OBJECTIVE: To determine the influence of the Oncotype Dx assay on the treatment of patients with Estrogen Receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative, axillary lymph node-negative or micrometastatic carcinoma of t